Aktienanalyse zu Jazz Pharmaceuticals PLC (JAZZ)JAZZJazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Jazz Pharmaceuticals is currently a hold. The stock's current price is $210.23, with a forward P/E ratio of 10.89, suggesting it may be undervalued compared to its earnings potential. However, the RSI is at 24.01, indicating that the stock is oversold, and the recent 5-day change is -3.75%, reflecting downward momentum. The main risk is the recent volatility in earnings, with a net income of -$71.8 million in Q2 2025, which raises concerns about profitability moving forward.

21 analysts cover JAZZ: 16 rate it Buy, 5 Hold and 0 Sell. The average price target is 218.92.